Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1993-01-08
1999-01-19
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241361, 4241521, 4241541, 5303873, 5303871, A61K 39395, A61K 3940, A61K 3942, C12P 2108
Patent
active
058611568
ABSTRACT:
Methods of delivering agents to target cells including methods of immunotherapy, are disclosed in which monospecific binding proteins are administered to a host and bind to target cells followed by administration of multivalent antibodies to direct the agents to the target cells.
REFERENCES:
patent: 4676980 (1987-06-01), Segal et al.
patent: 5084398 (1992-01-01), Huston et al.
patent: 5091513 (1992-02-01), Huston et al.
Souza et al. PNAS vol. 92 p. 959-963, 1995.
Osband et al. Immunology Today vol. 11 No. 6. p. 193 1990.
Monclonal Antibodies. (Waldmann ed.) 1988 pp. 31-49.
Schlom Molecular Foundation of Oncology ed. Samuel Broder 1991 p. 95-134.
Genes and Cancer (Hird) ed. Carney and Sikora. 1990 pp. 183-189.
Waldmann Science vol. 252 1991 p. 1657.
Harris et al. Tibteln Vol. 11 1993, p. 42.
Int J. Cancer. Sugita et al. 37 1986 p. 351-357.
Friedman, P.N., et al., "Antitumor Activity of the Single-Chain Immunotoxin BR96 sFv-PE40 Against Established Breast and Lung Tumor Xenografts," Chemical Abstracts, 119:437-437 Abstract No. 119:4237y (1993).
Friedman, P.N. et al., "BR96 sFv-PE40, a Potent Single-Chain Immunotoxin that Selectively Kills Carcinoma Cells, " Chemical Abstracts, 118:32 Abstracts No. 118:93926z (1993).
Huston, J.S., et al., "Medical Applications of Single-Chain Antibodies," Intern. Rev. Immunol., 10:195-217 (1993).
Gilliland, L.K., et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," Proc. Natl. Acad. Sci. USA, 85:7719-7723 (1988).
Segal, D.M., et al., "Bispecific Antibodies in Cancer Treatment" Biological Therapy of Cancer vol. 2 No. 4 pp. 1-12 (1992).
Staerz, U.D. et al., "Hybrid antibody-mediated Lysis of virus-infected cells," Eur. J. Immunol. 17:571-574 (1987).
Milenic, D.E., et al., "Constructions, Binding Properties, Metabolism, and Tumor Targeting of a Single-Chain Fv Derived from the Pancarcinoma Monoclonal Antibody CC49", Cancer Research, 51:6363-6371 (1991).
Karpovsky, B., et al., "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anto-Fc.gamma. Receptor Antibodies," J. of Exp. Med. 160:1686-1701 (1984).
Titus, J.A., et al., "Human T Cells Targeted with Anti-T3 Cross-Linked to Antitumor Antibody Prevent Tumor Growth in Nude Mice," J. of Immunol., 138:4018-4022 (1987).
Staerz, U.D. and Bevan, M.J., "Hybrid hybridoma producing a bispecific monoclonal antilbody that can focus effector T-cell activity," Proc. Natl. Acad. Sci. USA, 83:1453-1457 (1986).
Yokota, T., et al., "Rapid Tumor Penetration of a Single-Chain Fv and Comparison with Other Immunoglobulin Forms," Cancer Research, 52:3402-3408 (1992).
Marchalonis J.J. and Galbraith, R.M, "Receptors on Lymphoid Cells: An Overview," Meth. in Enzymol.. 150:377-389 (1987).
Segal, D.M. and Snider, D.P., "targeting and Activation of Cytotoxic Lymphocytes," Chem. Immunol., 47:179-213 (1989).
Perez, P., et al., "Specific targeting of cytotoxic T Cells by antil-T3 linked to anti-target cell antibody, " Nature, 316:354-356 (1985).
Bosslet, K., et al., "Two-phase radioimmunotherapy using bispecific monoclonal antibodies (bs MAbs)," Cancer Treatment Reviews 17:355-356 (1990).
Segal, D.M., et al., "Targeting of cytotoxic cells with cross-linked antibody heteroaggregates," Mol. Immunol., 23(11):1211-1214 (1986).
Snider, D.P. and Segal, D.M. "Efficiency of antigen presentation after antigen targeting to surface IgD, IgM, MCH, Fc.gamma. RII, and B220 Molecules on Murine Splenic B Cells", J. of Immunol., 143(1):59-65 (1989).
Huston, J.S., et al., "Multisite association by recombinant proteins can enhance binding selectivity," Biophysical Journal, 62:87-91 (1992).
Segal, D.M., et al., "Targeted cytotoxic Cells as a Novel Form of Cancer Immunotherapy," Mol. Immunol., 25(11):1099-1103 (1988).
Segal, D.M., et al., "Targeting of Cytotoxic Cells with Heterocrosslinked Antibodies," Cancer Invest.,. 6(1):83-92 (1988).
Caron, P.C., et al., "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies," J. Exp. Med., 176:1191-1195 (1992).
Bosslet, K., et al., "Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy," Br. J. Cancer, 63:681-686 (1991).
Shin, S-U., and Morrison, S.L., "Production and Properties of Chimeric Antibody Molecules," Meth. in Enzymol., 178:459-476 (1989).
Snider, D.P., et al., "Enhanced Antigen Immunogenicity Induced by Bispecific Antibodies," J. Exp. Med., 171:1957-1963 (1990).
George Andrew J. T.
Huston James S.
Segal David M.
Creative BioMolecules
Eyler Yvonne
Feisee Lila
The United States of America as represented by the Department of
LandOfFree
Methods of delivering agents to target cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of delivering agents to target cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of delivering agents to target cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1244994